Tandem Diabetes Care (TNDM) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Worldwide Sales: $255 million, up 6% year-over-year (5% in constant currency).

Pump Shipments: Approximately 33,000 pumps shipped worldwide, with U.S. shipments at 22,000 (up 7% year-over-year).

Gross Margin: 57%, an increase of 5 percentage points year-over-year.

Operating Expenses: $159 million, flat year-over-year.

Adjusted EBITDA Margin: Increased to 3% of sales.

Cash and Investments: $456 million at quarter-end, down from $570 million in Q1 due to strategic investments.

2Strategic Updates and Business Highlights

PayGo Reimbursement Model: Launched in March, with 10% of U.S. sales through pharmacy channels in Q2. This model aims to improve access and affordability for customers.

Commercial Organization Modernization: New CRM system deployed to enhance sales efficiency and support international launches.

Product Innovations: Continued expansion of the product portfolio, including the FDA submission for the Mobi tubeless feature and improvements in CGM compatibility.

International Growth: 19% year-over-year increase in international pump shipments, with direct sales in Europe beginning to show traction.

3Forward Guidance and Outlook

2026 Sales Guidance: Expected worldwide sales between $1.065 billion and $1.085 billion, with U.S. sales between $730 million and $745 million.

Q3 Expectations: Projected sales of approximately $265 million, with gross margin around 56% and adjusted EBITDA margin of about 2%.

Long-term Outlook: Confidence in achieving higher margins in Q4 due to increased pharmacy supply orders and seasonal sales dynamics.

4Bad News, Challenges, or Points of Concern

Infusion Set Supply Constraints: Ongoing issues with a key supplier affected sales and fulfillment, particularly in international markets.

Pharmacy Channel Transition: Initial headwinds from the PayGo model, with an estimated $8 million impact on revenue due to upfront reimbursement differences.

Competitive Pressures: Concerns about retention rates in the type 2 diabetes segment, with competitors facing similar challenges.

New Start Growth: Flat year-over-year new starts in Q2, requiring a significant increase in the second half to meet annual guidance.

5Notable Q&A Insights

Pharmacy Transition: Management expressed confidence in the PayGo model despite early learning curves, indicating that efficiencies are expected to improve over time.

Type 2 Market Dynamics: Retention rates for type 2 patients are slightly higher than type 1, with a focus on attracting patients likely to succeed with pump therapy.

Gross Margin Expectations: Although Q2 margins were strong, management anticipates a sequential decline in Q3 due to the dynamics of pharmacy adoption and pricing strategies.

Mobi Tubeless Launch: The product is under FDA review, with plans for a scaled launch in the second half of 2026, expected to significantly impact revenue and market position. Overall, Tandem Diabetes Care demonstrated solid operational momentum and strategic advancements in Q2 2026, despite facing challenges related to supply constraints and competitive pressures. The company remains optimistic about future growth, particularly with the rollout of new technologies and the PayGo reimbursement model.